PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia

BACKGROUND: T cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype that comprises 10–15% of childhood and 20–25% of adult ALL cases. Over 70% of T-ALL patients harbor activating mutations in the NOTCH1 signaling pathway and are predicted to be sensitive to gamma-secretase inhibitors. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Govaerts, Inge, Prieto, Cristina, Vandersmissen, Charlien, Gielen, Olga, Jacobs, Kris, Provost, Sarah, Nittner, David, Maertens, Johan, Boeckx, Nancy, De Keersmaecker, Kim, Segers, Heidi, Cools, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223323/
https://www.ncbi.nlm.nih.gov/pubmed/34167562
http://dx.doi.org/10.1186/s13045-021-01114-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223323/
https://www.ncbi.nlm.nih.gov/pubmed/34167562
http://dx.doi.org/10.1186/s13045-021-01114-1

Ejemplares similares